ArticleInternational journal of clinical oncology2019
Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Article in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Phase II clinical trial to study the safety and efficacy of combined S-1 + oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients.International journal of clinical oncology · 2023Trial
- Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.Scientific reports · 2021Trial
- Body composition-based nutritional status during neoadjuvant chemotherapy and its association with relative dose intensity and hematologic toxicity in patients with gastric cancer.Frontiers in nutrition · 2026Article
- From mechanisms to management: a comprehensive review of sarcopenia in gastric cancer.Frontiers in nutrition · 2026Review
- Survival Benefit of Adjuvant S-1 Chemotherapy in Patients Aged ≥ 80 Years with Gastric Cancer after Curative Resection: A Multicenter Cohort Study.Annals of surgical oncology · 2026Article
- EarlyWorld journal of gastroenterology · 2025Article
- Article
- Disparities in overall survival of gastric cancer patients after radical gastrectomy: an age and rural-urban residence-based cohort study with propensity score matching analysis.Scientific reports · 2025Article
- Advantages of adjuvant chemotherapy using S-1 following minimally invasive gastrectomy for gastric cancer versus open surgery: a propensity score-matched analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer.Surgery today · 2024Article
- Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study.Annals of surgical oncology · 2023Article
- Impact of loss of skeletal muscle mass within 6-12 months after gastrectomy and S1 adjuvant chemotherapy on the survival prognosis of elderly patients with gastric cancer.Surgery today · 2022Article
- Helicobacter pylori Modulated Host Immunity in Gastric Cancer Patients With S-1 Adjuvant Chemotherapy.Journal of the National Cancer Institute · 2022Article
- The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients.Journal of gastrointestinal oncology · 2021Article
- Cumulative total S-1 dose in adjuvant chemotherapy affects the long-term outcome following curative gastrectomy for gastric cancer.American journal of cancer research · 2021Article
- Clinical impact of postoperative interval until adjuvant chemotherapy following curative gastrectomy for advanced gastric cancer.Journal of Cancer · 2021Article
- Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.International journal of clinical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHow the interval between surgery and S-1 adjuvant chemotherapy (ACT), and S-1 relative dose intensity (RDI) affect prognosis in patients with stage II/III gastric cancer who undergo gastrectomy with D2 lymph node dissection followed by S-1 ACT is unclear.
methodsWe enrolled 95 patients with histopathologically confirmed gastric adenocarcinoma treated with gastrectomy with D2 dissection, followed by S-1 ACT.
resultsPer ROC analysis, we used 32 days as the optimal cut-off interval to divide patients into the delayed group (started ACT ≥ 32 days) and the non-delayed group ( < 32 days). Their 5-year overall survival (OS) rates differed significantly (delayed: 54.2%, non-delayed: 85.4%; P < 0.0001). Per ROC analysis of patients without recurrence within 1 year post-surgery, patients were divided into the high RDI (RDI
conclusionsEarly initiation and sufficient RDI for S-1 ACT can improve the prognosis of patients with stage II/III gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.